Clinical Trials

Find a Trial

Trial Summary

Principal InvestigatorPradhan, Kamnesh
PhasePhase III
Age GroupChildren
TitleTreatment of Patients with Newly Diagnosed Standard Risk B-Precursor Acute Lymphoblastic Leukemia (ALL)
DescriptionThis partially randomized phase III clinical trial is studying different combinations of risk-adapted chemotherapy regimens and their side effects and comparing how well they work in treating younger patients with newly diagnosed standard-risk acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells.
Key EligibilityIn order to be eligible to take part in this trial, patients must meet the following criteria:

  • Be between 1 and 30 years of age
  • Have newly diagnosed NCI Standard Risk B-ALL or B-LLy Murphy Stages I or II; patients with Down syndrome are also eligible
  • Be enrolled on AALL08B1 prior to treatment and enrollment on AALL0932
For a full list of participation criteria, please visit
Applicable Disease SitesLeukemia (Child)
Participating InstitutionsIU Health North Hospital
  • IU Health North Hospital
Indiana University (IU)
  • Indiana University Hospital / IU Simon Cancer Center
  • Riley Hospital for Children
Treatment TypeTreatment
ContactMelissa Lee, Phone: 317-944-4281
Pager: 312-1228